Golimumab is often a human monoclonal antibody administered once per month by subcutaneous injection. While it's an identical safety and efficacy profile to other TNFi, golimumab is much less helpful than other TNFi in people who have unsuccessful multiple biological remedies. The authors thank the College of Oradea, taking into https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/